Skip to main content
OpenTrials
Completed

NCT Number: NCT03612986

Clinical Trial to Evaluate the Effects of a Nutraceutical in Patients Affected by Knee Osteoarthritis

Double blind, placebo controlled trial to evaluate the effects of a nutraceutical containing high-molecular-weight hyaluronic acid (HA) and acetyl-11-keto-beta-boswellicacid (AKBA) in patients affected by knee osteoarthritis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Opera Contract Research Organization S.r.l.

Timișoara, Timiș County, 300209, Romania

About this study

The primary objective of the trial is to assess the feasibility of implementing Ultrasonography and Range of Motion (ROM) as objective measurements to correlate the improvement of the knee mobility with the pain reduction of the affected knee in the patients assuming nutraceutical containing hyaluronic acid (HA).

The secondary objectives of the trial are:

  • to assess the feasibility of implementing Actigraphy as objective measurements to correlate the improvement of the knee mobility with the pain reduction (optional).
  • to evaluate the enrollment rate in one month.

The explorative objectives of the trial are:

  • Preliminary data on efficacy of the tested product.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any gender and age from 45 to 70 years
  • Symptomatic osteoarthritis (OA) of the knee with mild joint discomfort for at least 6 months prior to enrollment, following ACR criteria with history and physical examination(44). Subjects diagnosed with bilateral knee OA will be asked to specify the most affected knee at baseline, and this knee will be evaluated throughout the study period.
  • Available confirmatory X-ray (performed within the previous 6 months) diagnosis (Kellgren/Lawrence score 2) at the evaluated knee joint(45).
  • Subjects experienced pain for at least 15 of the 30 days prior to the start of the study.

Exclusion criteria

  • Subjects who have any inflammatory arthritic condition (different from the OA of the knee), fibromyalgia, multiple sclerosis or autoimmune disorder.
  • Treatment with oral corticosteroids within 4 weeks before screening.
  • Intra-articular injections of HA or corticosteroids in the target joint within 3 months before screening.
  • Treatment with anti-inflammatory or chondroprotective drugs (chondroitin sulfate, glucosamine, methylsulfonylmethane, HA, diacerein) 2 weeks before the selection.
  • HA-containing nutritional supplements or cosmetics during the month before the study.
  • Previous surgical treatment of knee joint(s) or its necessity necessity for osteoarthritis (high tibial osteotomy, arthroplasty); complication(s) necessary for hospitalization and surgical treatment.
  • Significant injury to the target joint within the past 6 months prior to screening (identified from medical history).
  • Subjects following an energy-restricted diet for weight loss.
  • Pregnant women, nursing mothers, or women (only if childbearing potential) not using adequate methods of contraception.
  • Subjects with cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other medical or psychiatric condition that, in the opinion of the investigator, would compromise participation or be likely to lead to hospitalization during the course of the study.
  • Participation in an interventional clinical study in the previous 30 days.
  • Presence of any clinically significant medical condition judged by the investigator to preclude the patient's inclusion in the study.

Treatment and study plan

SYALOX® 300 Plus

Dietary Supplement

Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis

Placebo

Dietary Supplement

Placebo comparator. No chemical effect expected

Primary outcomes

  1. Visual Analogue Scale (VAS) results at rest. Change is being assessed.

    Time frame: week 0, 4 and 16

    Change in Visual Analogue Scale (VAS) results at rest, measured in mm

  2. Knee Range of Motion (ROM) results measured by goniometer. Change is being assessed.

    Time frame: week 0, 4 and 16

    Change in Range of Motion (ROM) results, measured in grades by goniometer.

Secondary outcomes

  1. Visual Analogue Scale (VAS) results at moving. Change is being assessed.

    Time frame: week 0, 4 and 16

    Change in Visual Analogue Scale (VAS) results at moving, measured in mm

  2. Visual Analogue Scale (VAS) results on pressing. Change is being assessed.

    Time frame: week 0, 4 and 16

    Change in Visual Analogue Scale (VAS) results at pressing, measured in mm

  3. Ultrasonography parameters results. Change is being assessed.

    Time frame: week 0 and 16

    Change of presence or absence of Synovial fluid, Articular cartilage damage, Medial meniscal protrusion, Lateral meniscal protrusion, Medial osteophytes, Lateral osteophytes, Enthesopathies, Effusion is being assessed.

  4. Knee injury and Osteoarthritis Outcome Score (KOOS). Change is being assessed.

    Time frame: week 0, 4 and 16

    Change in parameters of quality of life will be assessed through Knee injury and Osteoarthritis Outcome Score (KOOS).

  5. Index of Severity for Osteoarthritis of the Knee by Lequesne et al. Change is being assessed.

    Time frame: week 0, 4 and 16

    Change in parameters of quality of life will be assessed through Index of Severity for Osteoarthritis of the Knee by Lequesne et al.

  6. Knee movement results using an actimeter (accelerometer). Change is being assessed.

    Time frame: week 0 and 16

    Knee movement based on acceleration results using an actimeter, device based on an accelerometer. The results will be measured in meter/second squared (m/s2) Change is being assessed.

Other outcomes

  1. Safety outcomes assessed by number of adverse events (AE)/serious adverse events (SAE)

    Time frame: day 0, week 4 and 16

    Adverse events (AE)/serious adverse events (SAE) (number of events occured, related to the investigational product administration)

  2. Safety assessment based on rescue medication (Paracetamol 500mg) administration

    Time frame: day 0, week 4 and 16

    Safety assessed by the number of rescue medication tablets administered daily.

Sponsors and collaborators

Lead sponsor

River Pharma S.r.l.

Other

Registry information

Official study title

Double Blind, Placebo Controlled Trial to Evaluate the Effects of a Nutraceutical Containing High-Molecular-Weight Hyaluronic Acid (HA) and Acetyl-11-Keto-Beta-Boswellic Acid (AKBA) in Patients Affected by Knee Osteoarthritis

Acronym: SMILE

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Aug 2, 2018
Registry last updated
Oct 2, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.